Pain & Central Nervous System Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain & Central Nervous System Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chronic Pain
Promising preclinical data published on pain therapy
March 31st, 2003
Newron Pharmaceuticals, SpA, announced the publication of positive preclinical data on NW-1029, the company's lead product in its pain program. The data show that NW-1029 has potent and long-lasting antihyperalgesic and antiallodynic activity in models of chronic pain, with an excellent therapeutic index. NW-1029 was also well tolerated without signs of neurological impairment at high doses. Clinical trials have been initiated. Details of the studies were published in a paper entitled "Antiallodynic effect of NW-1029, a novel Na+ channel blocker, in experimental animal models of inflammatory and neuropathic pain" that appears in Pain,...
Source: Pain & Central Nervous System Week (2003-03-31)
|
